Uroplasty, Inc., incorporated in the state of Minnesota in 1992, is a global company that develops, manufactures and markets innovative, proprietary products for the treatment of voiding dysfunctions. In 1996, Uroplasty became a reporting company pursuant to registration filed with the Securities and Exchange Commission.
Uroplasty, Inc. is the financial, operations and regulatory headquarters for the company and is located in Minnetonka, Minnesota, United States. Uroplasty, Inc. owns and operates a Dutch subsidiary located in Geleen, The Netherlands. The Geleen office serves as the international sales headquarters for the company, which relies on a network of local distributors to sell in markets outside the United States. Uroplasty, Ltd serves the United Kingdom with a direct sales force.
Key Company Milestones
Category 1 CPT Code, 64566, specific to PTNS, effective January 1, 2011.
The United Kingdom's National Institute of Clinical Excellence (NICE) issues a guidance for the use of PTNS in the treatment of Fecal Incontinence. Urgent PC is not cleared for the treatment of fecal incontinence in the United States.
The United Kingdom's National Institute of Clinical Excellence (NICE) issues a guidance for the use of PTNS in the treatment of Overactive Bladder.
The American Medical Association establishes a new Category I CPT Code, 64566, specific to PTNS.
Randomized studies are conducted comparing Urgent PC to medical and sham treatment.
Uroplasty develops the next generation of Urgent PC featuring a new control interface and an ergonomic design.
The FDA grants PMA approval to Macroplastique for the treatment of female stress urinary incontinence (SUI) primarily due to intrinsic sphincter deficiency (ISD).
The Macroplastique IDE study is completed.
Uroplasty updates the Urgent PC technology and obtains 510(k) clearance for the Urgent PC stimulator and lead set.
Uroplasty begins to commercialize Urgent PC in the United States for the treatment of overactive bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence.
Uroplasty signs a licensing agreement with Cystomedix, Inc. to acquire the Urgent PC technology, the only FDA-cleared product to deliver percutaneous tibial nerve stimulation (PTNS) for the treatment of Overactive Bladder and the associated symptoms of urinary urgency, urinary frequency and urge incontinence
Macroplastique earns CE Mark approval for PTQ implants, a tissue bulking agent used for the treatment of fecal incontinence.
Uroplasty changes the name of Bioplastique to VOX Implants for vocal cord rehabilitation.
The first patient is enrolled in the Macroplastique IDE clinical study. Enrollment for this two year study continues until 2003.
The MIS receives CE Mark approval in the European Union.
The FDA grants Investigational Device Exemption (IDE) approval to initiate a clinical study of Macroplastique for the treatment of female stress urinary incontinence in the USA.
The Macroplastique Implantation System (MIS) is developed to facilitate non-endoscopic placement of Macroplastique for female SUI treatment.
Macroplastique is approved for sale in Canada.
Macroplastique is the first tissue bulking agent to gain CE Mark Authorization in Europe. Uroplasty also receives CE Mark Authorization for the tissue bulking agent Bioplastique used for vocal cord rehabilitation.
The first peer-reviewed publication describing 3 year follow-up results for Macroplastique for the treatment of SUI is published in the British Journal of Urology.
Uroplasty's quality system receives ISO 9001 certification from AMTAC Certification Services (now a subsidiary of Intertek).
Urologists from the United Kingdom present their initial results using Macroplastique at worldwide Urology conferences including the American Urological Association (AUA), the International Continence Society (ICS), and the European Association of Urology (EAU).
Uroplasty is incorporated in the state of Minnesota to focus exclusively on the development of Macroplastique and other tissue bulking agent solutions.
Uroplasty opens its European Headquarters based in The Netherlands (Uroplasty BV).
Macroplastique is first used in the United Kingdom for the treatment of Vesicoureteral Reflux (VUR) and Stress Urinary Incontinence (SUI).
Arthur Beisang, Jr., Robert Ersek, M.D., and Arthur Beisang III, M.D., invent and refine a process for suspending textured silicone elastomer implants in a PVP hydrogel. This technology was used to create a tissue bulking agent that would become Macroplastique.
Tel: (1) 866 258 2182
Tel: +00 (1) 952 426 6140
U.S. Product Inquiries
Tel: (1) 866 258 2182
International Product Inquiries
Tel: +31 (0) 46 423 79 20
UK Product Inquiries
Tel: +44 800 032 5964